SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus

Revenue guidance is $685–$705 million, driven by four CNS products, with Qelbree and Onapgo showing strong growth. Onapgo faces supply constraints, while Zurzuvae is expanding in postpartum depression. Business development and pipeline expansion remain key priorities.

Based on Supernus Pharmaceuticals, Inc. [SUPN] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 17 2025